CN113519846A

CN113519846A - Fish oil extract multi-algae tablet capable of reducing blood fat and enhancing fat metabolism in vivo and preparation method thereof

Info

Publication number: CN113519846A
Application number: CN202110804034.6A
Authority: CN
Inventors: 何海
Original assignee: Zhuhai Zhongshi Guopeptide Health Technology Co ltd
Current assignee: Zhuhai Zhongshi Guopeptide Health Technology Co ltd
Priority date: 2021-07-16
Filing date: 2021-07-16
Publication date: 2021-10-22

Abstract

The application provides fish oil extract microalgae tablets capable of reducing blood fat and enhancing fat metabolism in vivo and a preparation method thereof, belonging to the technical field of health-care food. The fish oil extract multi-algae tablet comprises the following raw materials in parts by weight: 12-30 parts of fish oil extract, 5-16 parts of spirulina platensis, 5-12 parts of chlorella pyrenoidosa, 1-8 parts of haematococcus pluvialis, 1-8 parts of euglena and 0.05-0.6 part of dunaliella salina extract; wherein DHA content of the fish oil extract is not less than 125 mg/g. Regulating blood lipid by fish oil extract; extracts of spirulina platensis, chlorella pyrenoidosa, haematococcus pluvialis, euglena, dunaliella salina and the like which are unicellular eukaryotes have the effects of regulating osmotic pressure in vivo, relieving stress, and promoting fat metabolism and protein synthesis. It has effects of reducing blood lipid and enhancing fat metabolism, and is beneficial for enhancing fat metabolism of obese people and hyperlipemia caused by obesity.

Description

Fish oil extract multi-algae tablet capable of reducing blood fat and enhancing fat metabolism in vivo and preparation method thereof

Technical Field

The application relates to the technical field of health-care food, in particular to fish oil extract microalgae tablets capable of reducing blood fat and enhancing fat metabolism in vivo and a preparation method thereof.

Background

At present, with the development of society, the living standard of people is continuously improved, the change of dietary structure and life style, the crowds with obesity and hyperlipidemia are increasing, and the two are frequently cause and effect and occur together. The fat people are often accompanied with disorder of lipid metabolism due to high body fat, and the hyperlipidemia phenomena mainly manifested by triglyceride increase, high-density lipoprotein level reduction and cholesterol level increase appear. Obesity with hyperlipidemia can easily lead to visceral disorders such as fatty liver, which is wrapped by fat.

It was found that the mean plasma cholesterol and triacylglycerol levels were significantly higher in obese people than in non-obese people of the same age. In addition to the significant positive correlation between Body Mass Index (BMI) and blood lipid levels, the distribution of body fat is also closely related to plasma lipoprotein levels. Generally, people with abdominal obesity are more susceptible to hyperlipidemia. The blood lipid disorder can also be recovered to normal after the weight of the obese people is reduced. However, no effective health care product can better improve fat metabolism in the body of the obese people and simultaneously improve the associated hyperlipidemia and other problems of the obese people at present.

Disclosure of Invention

In order to achieve the above objects, the present application provides a fish oil extract microalgae tablet capable of reducing blood lipid and enhancing body fat metabolism and a preparation method thereof, which has the effects of reducing blood lipid and enhancing body fat metabolism, is beneficial to enhancing body fat metabolism of obese people, and simultaneously improves hyperlipidemia of obese people.

In a first aspect, an embodiment of the application provides a fish oil extract multi-algae tablet capable of reducing blood fat and enhancing fat metabolism in vivo, which comprises the following raw materials in parts by weight: 12-30 parts of fish oil extract, 5-16 parts of spirulina platensis, 5-12 parts of chlorella pyrenoidosa, 1-8 parts of haematococcus pluvialis, 1-8 parts of euglena, 0.05-0.6 part of dunaliella salina extract and auxiliary materials; wherein DHA content of the fish oil extract is not less than 125 mg/g.

Optionally, the auxiliary material is selected from one of sorbitol, microcrystalline cellulose and isomalt.

Preferably, the auxiliary material is 50-60 parts of sorbitol according to the mass parts.

Preferably, the raw materials comprise, by mass: 50-58 parts of sorbitol, 15-25 parts of fish oil extract, 8-15 parts of spirulina platensis, 7-11 parts of chlorella pyrenoidosa, 2-6 parts of haematococcus pluvialis, 2-6 parts of euglena and 0.1-0.4 part of dunaliella salina extract; wherein the DHA content of the fish oil extract is not less than 125 mg/g.

More preferably, the fish oil extract algae-laden tablets are prepared from the following raw materials: 52-55 parts of sorbitol, 18-24 parts of fish oil extract, 9-13 parts of spirulina platensis, 8-9 parts of chlorella pyrenoidosa, 3-5 parts of haematococcus pluvialis, 3-5 parts of euglena and 0.1-0.3 part of dunaliella salina extract; wherein the DHA content of the fish oil extract is not less than 125 mg/g.

Optionally, the fish oil extract multi-algae tablet comprises the following raw materials: 54 parts of sorbitol, 20 parts of fish oil extract, 9.6 parts of spirulina platensis, 8.2 parts of chlorella pyrenoidosa, 4 parts of haematococcus pluvialis, 4 parts of euglena and 0.2 part of dunaliella salina extract; the DHA content of the fish oil extract is not less than 125 mg/g.

Optionally, the fish oil extract multi-algae tablet comprises the following raw materials: 52 parts of sorbitol, 17.7 parts of fish oil extract, 12 parts of spirulina platensis, 10 parts of chlorella pyrenoidosa, 3 parts of haematococcus pluvialis, 5 parts of euglena and 0.3 part of dunaliella salina extract; the DHA content of the fish oil extract is not less than 125 mg/g.

Optionally, the fish oil extract multi-algae tablet comprises the following raw materials: 56 parts of sorbitol, 20 parts of fish oil extract, 9 parts of spirulina platensis, 8 parts of chlorella pyrenoidosa, 3.7 parts of haematococcus pluvialis, 5 parts of euglena and 0.3 part of dunaliella salina extract; the DHA content of the fish oil extract is not less than 125 mg/g.

Optionally, the DHA content of the fish oil extract is not less than 135 mg/g.

Preferably, the DHA content of the fish oil extract is not less than 150 mg/g.

More preferably, the EPA content of the fish oil extract is more than or equal to 80 mg/g.

More preferably, the EPA content of the fish oil extract is more than or equal to 95 mg/g.

Optionally, the total content of DHA and EPA in the fish oil extract is more than or equal to 230 mg/g.

Optionally, the water content of the fish oil extract is less than or equal to 1.0%.

According to the second aspect, the application provides a preparation method of fish oil extract multi-algae tablets capable of reducing blood fat and enhancing in vivo fat metabolism, the fish oil extract, the spirulina platensis, the chlorella pyrenoidosa, the haematococcus pluvialis, the euglena and the dunaliella salina are weighed according to parts by mass, the raw materials are preheated and uniformly mixed, water is added for granulation, then drying is carried out, and the sorbitol is added for mixing and tabletting.

Optionally, the preheating temperature during the raw material mixing is 50-60 ℃.

Specifically, the preheating temperature for the raw material mixing is 50 ℃, 52 ℃, 54 ℃, 56 ℃, 58 ℃ or 60 ℃.

Optionally, the mixing and stirring time of the raw materials is 20-40 min.

Specifically, the raw materials are mixed and stirred for 20min, 25min, 30min, 35min or 40 min.

Preferably, the temperature of the added water is 38 ℃ to 42 ℃.

Preferably, the raw materials further comprise the steps of sterilizing and sieving with a 40-mesh sieve before mixing.

Optionally, the drying temperature is 55-60 deg.C, and the water content of the dried granule is 3-5 wt%.

Specifically, the moisture content of the dried granules was 3%, 3.5%, 4%, 4.5%, or 5%.

The invention has the beneficial effects that:

according to the fish oil extract algae tablet, on one hand, the blood fat is adjusted through the fish oil extract; on the other hand, various algae such as spirulina platensis, chlorella pyrenoidosa, haematococcus pluvialis, euglena, dunaliella salina extracts and the like are unicellular eukaryotes, have the functions of regulating osmotic pressure in vivo, relieving stress, promoting fat metabolism and protein synthesis and play an important role in the metabolism of nutrient substances. According to the invention, by mixing various algae and fish oil extracts according to a certain proportion, the cell activity is enhanced by enhancing the free radical metabolism, the beta-oxidation of long-chain fatty acid is promoted, the activity of a liposynthase is inhibited, the regulation and control effect on the fat metabolism is realized, the fat metabolism in vivo is enhanced, and meanwhile, the blood fat is reduced, and the hyperlipidemia and the fat problem in vivo of obese people are improved.

Drawings

In order to more clearly illustrate the technical solutions of the embodiments of the present application, the drawings that are required to be used in the embodiments will be briefly described below, it should be understood that the following drawings only illustrate some embodiments of the present application and therefore should not be considered as limiting the scope, and for those skilled in the art, other related drawings can be obtained from the drawings without inventive effort.

Fig. 1 is a flow chart of a preparation process of a fish oil extract multi-algae tablet provided by the application;

fig. 2 is a graph comparing visceral fat areas of the experimental group and the control group.

Detailed Description

In order to make the objects, technical solutions and advantages of the embodiments of the present application clearer, the technical solutions in the embodiments of the present application will be clearly and completely described below with reference to the drawings in the embodiments of the present application, and it is obvious that the described embodiments are some embodiments of the present application, but not all embodiments.

The application provides a fish oil extract multi-algae tablet capable of reducing blood fat and enhancing fat metabolism in vivo, which comprises the following raw materials in parts by mass: 12-30 parts of fish oil extract, 5-16 parts of spirulina platensis, 5-12 parts of chlorella pyrenoidosa, 1-8 parts of haematococcus pluvialis, 1-8 parts of euglena, 0.05-0.6 part of dunaliella salina extract and auxiliary materials; wherein DHA content of the fish oil extract is not less than 125 mg/g.

Wherein, the fish oil extract is the short name of unsaturated fat in deep-sea fish. The fish oil extract is an extract extracted from oil extracted from fatty fish, and has effects of regulating blood lipid, etc. and contains DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) as main effective components. Fish oil extracts were not fish oils, as shown in table 1:

TABLE 1 comparison of ingredients of fish oil and fish oil extracts

	Fish oil	Fish oil extract
			Traits	Light yellow liquid	Powder of
DHA content	≥36mg/g	≥125mg/g
			EPA content	≥27mg/g	≥80mg/g
DHA + EPA content	≥144mg/g	≥230mg/g
			Moisture content	≤3.0％	≤1.0％

As can be seen from table 1, the fish oil extract requires a DHA content of no less than 125mg/g, which is significantly higher than fish oil DHA, EPA. Chlorella pyrenoidosa is rich in proteins, vitamins, minerals, dietary fibers, nucleic acids, chlorophyll, etc. The chlorella contains abundant chlorophyll in its cells, and has effects of adsorbing and removing toxin, and discharging harmful substances in vivo. In addition, Chlorella pyrenoidosa contains a precious growth factor (CGF) which promotes metabolism in the body.

Haematococcus pluvialis is an algae food rich in nutritive and medicinal values. The alga is named Haematococcus because it can accumulate a large amount of astaxanthin to give a red color. Haematococcus is an ideal source for producing natural astaxanthin in nature, and the astaxanthin which is the most efficient pure natural antioxidant discovered at present shows good biological activity in the aspects of free radical scavenging, anti-aging, anti-tumor, immunoregulation and the like.

Euglena, also known as chloromonas, is a single-cell eukaryote that is intermediate between animals and plants. The euglena polysaccharide can not be absorbed by human body, and can adsorb redundant substances in human body such as cholesterol, neutral fat, heavy metal, alcohol and the like to be discharged out of the body due to the internal porous structure, so that the euglena polysaccharide has the functions of strongly adsorbing fat and removing free radicals.

Dunaliella extract is a kind of unicellular eukaryotic green algae with extreme salt tolerance. The salt water is the only peculiar life which can survive in high-concentration saline water and is discovered at present, and is praised as 'a power source of cells' and 'a protective agent of life' by the world scientific community because of being rich in unique and abundant vital elements. Has effects in promoting normal lipid metabolism, reducing triglyceride in blood plasma, lowering blood sugar, and relieving insulin resistance.

Spirulina platensis is an original unicellular organism, and aggregates all balanced elements and bioactive substances for regulating, repairing and nourishing cells required by human body cells. The cell wall of spirulina is made of rare mucilaginous compounds, the most original single cell state is kept, and the spirulina can be quickly dissolved with human cells after entering a human body, and has excellent effects of directly nourishing, regulating, repairing and activating the human cells, strengthening the metabolism of the body and enhancing the body functions.

The fish oil extract-containing algae tablet regulates blood fat through the fish oil extract; on the other hand, the spirulina platensis, the chlorella pyrenoidosa, the haematococcus pluvialis, the euglena, the dunaliella salina extract and other various algae contain rich protein, vitamins, mineral substances, dietary fibers, nucleic acid, chlorophyll and the like, and have the effects of resisting oxidation, removing free radicals, enhancing cell metabolism and strengthening fat metabolism in vivo. The algae are unicellular eukaryotes, have the functions of regulating osmotic pressure in vivo, relieving stress, promoting fat metabolism and protein synthesis and play an important role in the metabolism of nutrient substances. The result reveals that the microalgae can enhance the cell activity by enhancing the free radical metabolism, promote the beta-oxidation of long-chain fatty acid and inhibit the activity of fat synthase, thereby having the regulation and control effect on the fat metabolism, enhancing the fat metabolism in vivo, reducing the blood fat and improving the hyperlipidemia and the fat problem in vivo of obese people.

Optionally, the adjuvant is sorbitol. Preferably, the auxiliary material is 50-60 parts of sorbitol according to the mass parts. Sorbitol can be used for tableting, and can be mixed with other raw materials to make tablets by adding the raw material.

More preferably, the fish oil extract algae-containing tablet comprises the following raw materials: 52-55 parts of sorbitol, 18-24 parts of fish oil extract, 9-13 parts of spirulina platensis, 8-9 parts of chlorella pyrenoidosa, 3-5 parts of haematococcus pluvialis, 3-5 parts of euglena and 0.1-0.3 part of dunaliella salina extract; wherein the DHA content of the fish oil extract is not less than 125 mg/g.

Illustratively, the fish oil extract algae-containing tablet comprises the following raw materials in parts by weight: 54 parts of sorbitol, 20 parts of fish oil extract, 9.6 parts of spirulina platensis, 8.2 parts of chlorella pyrenoidosa, 4 parts of haematococcus pluvialis, 4 parts of euglena and 0.2 part of dunaliella salina extract; the DHA content of the fish oil extract is not less than 125 mg/g.

Or the fish oil extract multi-algae tablet comprises the following raw materials: 52 parts of sorbitol, 17.7 parts of fish oil extract, 12 parts of spirulina platensis, 10 parts of chlorella pyrenoidosa, 3 parts of haematococcus pluvialis, 5 parts of euglena and 0.3 part of dunaliella salina extract; the DHA content of the fish oil extract is not less than 125 mg/g.

Or the fish oil extract multi-algae tablet comprises the following raw materials: 56 parts of sorbitol, 20 parts of fish oil extract, 9 parts of spirulina platensis, 8 parts of chlorella pyrenoidosa, 3.7 parts of haematococcus pluvialis, 5 parts of euglena and 0.3 part of dunaliella salina extract; the DHA content of the fish oil extract is not less than 125 mg/g.

Optionally, the DHA content of the fish oil extract is not less than 135 mg/g. Preferably, the DHA content of the fish oil extract is not less than 150 mg/g. More preferably, the EPA content of the fish oil extract is more than or equal to 80 mg/g. More preferably, the EPA content of the fish oil extract is more than or equal to 95 mg/g.

Fig. 1 is a flow chart of a preparation process of a fish oil extract microalgae tablet provided by the application. Referring to fig. 1, the preparation method includes:

s10, sterilizing the qualified fish oil extract, spirulina platensis, chlorella pyrenoidosa, haematococcus pluvialis, euglena and dunaliella salina extract respectively.

The quality inspection mainly detects the quality of raw materials, and whether the raw materials are in abnormal conditions such as overdue, metamorphism, mildewing and the like.

The sterilization mode is large bag sterilization, and specifically comprises the following steps: removing outer bags of raw materials in a workshop, starting a sterilization machine, wherein the time for the materials to pass through a tunnel is 60s, and when the materials pass through the sterilization tunnel, the distance between the bags is about 15cm, so as to ensure the surfaces of the materials to be effectively sterilized, and if no sterilization machine is used, starting an ultraviolet lamp in a room for sterilization for 30 min.

S20, respectively sieving the sterilized components with a 40-mesh sieve under the condition that the cleanliness of a production workshop is 10 ten thousand grades, mixing for 20-40min to obtain a mixture, and preheating the mixture while mixing, wherein the preheating temperature is 50-60 ℃.

Illustratively, the mixing time of the components is 20min, 25min, 30min, 35min or 40 min; the preheating temperature of the mixture is 50 ℃, 52 ℃, 54 ℃, 56 ℃, 58 ℃ or 60 ℃.

S30, adding water with the temperature of 38-42 ℃ for granulation under the condition that the cleanliness of a production workshop is 10 ten thousand grades, then drying under the condition that the temperature is 55-60 ℃ to ensure that the moisture content of the dried granules is 3-5%, and discharging.

Illustratively, the temperature of the water is 38 ℃, 39 ℃, 40 ℃, 41 ℃ or 42 ℃; drying at 55 deg.C, 56 deg.C, 57 deg.C, 58 deg.C, 59 deg.C or 60 deg.C; the moisture content of the dried granules was 3%, 3.5%, 4%, 4.5% or 5%.

Alternatively, the material may be granulated in a boiling granulator or in a rocking granulator.

S40, sieving the sorbitol with a 40-mesh sieve under the condition that the cleanliness of a production workshop is 10 ten thousand grades, mixing with the granules obtained in the step S30 for 20-40min, and tabletting. The tablet weight after tabletting is 0.25 g/tablet, the error of the tablet weight is within +/-5 percent, and the friability is less than or equal to 0.5 percent.

Optionally, the mixing time is 20min, 25min, 30min, 35min, or 40 min. After tabletting is finished, spot check is needed to detect the weight, hardness, friability and index components of the tablet.

And S50, subpackaging the qualified products in polyethylene plastic bottles containing drying agents after the products are subjected to sampling inspection, packaging, and warehousing after the products are qualified.

Wherein, the fish oil extract algae tablet is placed in a polyethylene plastic bottle with a drying agent by a filling mode, and is sealed by a heat seal sealing mode after being capped.

In the preparation method, the effective components of the fish oil extract microalgae tablet are mixed and granulated, and then the sorbitol is added for tabletting, so that the damage to various nutritional components in the fish oil extract microalgae tablet can be avoided during tabletting, and the fish oil extract microalgae tablet can be easily absorbed, so as to achieve the effects of reducing blood fat and enhancing fat metabolism in vivo. The fish oil extract-containing algae tablet has the advantages that on one hand, the fish oil extract is used for reducing blood fat; on the other hand, the spirulina platensis, the chlorella pyrenoidosa, the haematococcus pluvialis, the euglena, the dunaliella salina extract and other algae contain rich protein, vitamins, mineral substances, food fibers, nucleic acid, chlorophyll and the like, and the functions of resisting oxidation, removing free radicals, enhancing cell metabolism, enhancing fat metabolism in vivo and the like are further realized by mixing various algae according to a certain proportion and utilizing the mutual synergistic action among the various algae. The algae are unicellular eukaryotes, have the functions of regulating osmotic pressure in vivo, relieving stress, promoting fat metabolism and protein synthesis and play an important role in the metabolism of nutrient substances. The result reveals that the microalgae can enhance the cell activity by enhancing the free radical metabolism, promote the beta-oxidation of long-chain fatty acid and inhibit the activity of fat synthase, thereby having the regulation and control effect on the fat metabolism, enhancing the fat metabolism in vivo, reducing the blood fat and improving the hyperlipidemia and the fat problem in vivo of obese people.

Example 1:

the preparation method of the fish oil extract multi-algae tablet comprises the following steps:

(1) respectively detecting the raw material quality conditions of fish oil extract, spirulina platensis, chlorella pyrenoidosa, haematococcus pluvialis, euglena and dunaliella salina extract, and determining whether abnormal conditions such as overdue, metamorphism, mildewing and the like exist. Removing the raw materials of qualified fish oil extract, spirulina platensis, chlorella pyrenoidosa, haematococcus pluvialis, euglena and dunaliella salina extract from a workshop by using an outer bag, starting a sterilization machine, enabling the materials to pass through a tunnel for 60s, and paying attention to the fact that the distance between the bags is about 15cm when the materials pass through a sterilization tunnel, so as to ensure that the surfaces of the materials are effectively sterilized.

(2) Under the condition that the cleanliness of a production workshop is 10 ten thousand grade, the sterilized components are respectively sieved by a 40-mesh sieve, then 20 parts of fish oil extract (fish oil extract supplier production enterprises: Safty Olympic Biotech Co., Ltd., product model: DHA 40%), 9.6 parts of spirulina platensis, 8.2 parts of chlorella pyrenoidosa, 4 parts of haematococcus pluvialis, 4 parts of euglena and 0.2 part of dunaliella salina extract are respectively weighed, and then the components are mixed in a boiling granulator for 30min to obtain a mixture. And it was preheated to 56 ℃.

(3) Spraying water at 40 deg.C for granulating under the condition of cleanliness of 10 ten thousand grade in production workshop, drying at 55 deg.C to water content of 3-5%, and discharging.

(4) And (3) sieving sorbitol by a 40-mesh sieve under the condition that the cleanliness of a production workshop is 10 ten thousand, weighing 54 parts, mixing with the granules obtained in the step (3) for 30min, and tabletting. The tablet weight after tabletting is 0.25 g/tablet, the error of the tablet weight is within +/-5 percent, and the friability is less than or equal to 0.5 percent.

(5) And (4) performing sampling inspection on the tabletted product, subpackaging the product in a polyethylene plastic bottle with a drying agent after the sampling inspection is qualified, packaging, and warehousing after the detection is qualified.

Example 2

The preparation method is the same as that of example 1, except that:

52 parts of sorbitol, 17.7 parts of fish oil extract (fish oil extract supplier production enterprise: Western safe Olympic Biotechnology Co., Ltd., product model: DHA 40%), 12 parts of spirulina platensis, 10 parts of chlorella pyrenoidosa, 3 parts of haematococcus pluvialis, 5 parts of euglena and 0.3 part of dunaliella salina extract.

Example 3

The preparation method is the same as that of example 1, except that the raw materials in parts by weight are as follows:

56 parts of sorbitol, 20 parts of fish oil extract (fish oil extract supplier production enterprise: Western safe Olympic Biotechnology Co., Ltd., product model: DHA 40%), 9 parts of spirulina platensis, 8 parts of chlorella pyrenoidosa, 3.7 parts of haematococcus pluvialis, 5 parts of euglena and 0.3 part of dunaliella salina extract.

Experimental example 1

The male is a 36-year-old male with a height of 176cm, a weight of 85kg, a body mass index of 27.44 and a waist circumference of 98cm, and belongs to obese people. The fish oil extract, algae-laden tablets, provided in example 1, were ingested once a day, 10 tablets each, for 12 weeks, 0.25 grams per tablet, as follows in tables 1 and 2:

TABLE 1 comparison of body weight, waist circumference, and visceral fat data before and after 12 weeks of ingestion of fish oil extract Dunaliella tablets

As can be seen from table 1, after von willebrand disease was taken for 12 weeks, the fish oil extract microalgae tablet provided in example 1 of the present application was significantly reduced in body weight, significantly reduced in body mass index and waist circumference, and no longer had the problems of fatty liver, vascular plaque, liver fat mass, and pancreatic fat mass, and improved the hyperlipidemia and body fat problems of obese people.

TABLE 2 comparison of blood lipid data before and after 12 weeks for ingestion of fish oil extract Dunaliella tablets

As can be seen from table 2, after administering the fish oil extract microalgal tablet provided in example 1 of the present application for 12 weeks, the values of fibrinogen, glycated hemoglobin, total cholesterol, triacylglycerol, low-density lipoprotein cholesterol, and uric acid were all decreased, high-density lipoprotein cholesterol was increased, and the hyperlipidemia and body fat problems of obese persons were improved.

Experimental example 2

The subjects were analyzed for age 20-55 years, 53 obese-obese subjects (BMI: 24-30), wherein the BMI classification criteria are given in Table 3:

TABLE 3 BMI Classification criteria

53 patients with obesity were divided into an experimental group and a control group, wherein the experimental group comprises 27 fish oil extract algae tablets provided in example 1, each tablet comprises 0.25 g, 10 tablets each time, and is administered for 12 weeks; the control group was administered 0.25 g of the fish oil provided in example 1 once a day for 10 tablets for 12 weeks, and the visceral fat area of the two groups was compared as shown in fig. 2. As can be seen from fig. 2, the reduction of the visceral fat area of the person taking the fish oil extract diatom tablet provided in example 1 of the present application is very significant, which indicates that the fish oil extract diatom tablet provided in the present application has the efficacy of reducing blood lipid and enhancing fat metabolism in vivo.

The above description is only a preferred embodiment of the present application and is not intended to limit the present application, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, improvement and the like made within the spirit and principle of the present application shall be included in the protection scope of the present application.

Claims

1. A fish oil extract multi-algae tablet capable of reducing blood fat and enhancing fat metabolism in vivo is characterized by comprising the following raw materials in parts by weight: 12-30 parts of fish oil extract, 5-16 parts of spirulina platensis, 5-12 parts of chlorella pyrenoidosa, 1-8 parts of haematococcus pluvialis, 1-8 parts of euglena, 0.05-0.6 part of dunaliella salina extract and auxiliary materials; wherein the DHA content of the fish oil extract is not less than 125 mg/g.

2. The fish oil extract polyanemic tablet capable of reducing blood lipid and enhancing fat metabolism in vivo as claimed in claim 1, wherein the adjuvant is selected from one of sorbitol, microcrystalline cellulose and isomalt;

preferably, the auxiliary material is 50-60 parts of sorbitol in parts by mass;

3. The fish oil extract microalgae tablet capable of reducing blood lipid and enhancing fat metabolism in vivo according to claim 2, characterized in that the raw materials are: 52-55 parts of sorbitol, 18-24 parts of fish oil extract, 9-13 parts of spirulina platensis, 8-9 parts of chlorella pyrenoidosa, 3-5 parts of haematococcus pluvialis, 3-5 parts of euglena and 0.1-0.3 part of dunaliella salina extract; wherein the DHA content of the fish oil extract is not less than 125 mg/g.

4. The fish oil extract microalgae tablet capable of reducing blood lipid and enhancing fat metabolism in vivo according to claim 3, characterized in that the raw materials are: 54 parts of sorbitol, 20 parts of fish oil extract, 9.6 parts of spirulina platensis, 8.2 parts of chlorella pyrenoidosa, 4 parts of haematococcus pluvialis, 4 parts of euglena and 0.2 part of dunaliella salina extract; the DHA content of the fish oil extract is not less than 125 mg/g; or

The raw materials are as follows: 52 parts of sorbitol, 17.7 parts of fish oil extract, 12 parts of spirulina platensis, 10 parts of chlorella pyrenoidosa, 3 parts of haematococcus pluvialis, 5 parts of euglena and 0.3 part of dunaliella salina extract; the DHA content of the fish oil extract is not less than 125 mg/g; or

The raw materials are as follows: 56 parts of sorbitol, 20 parts of fish oil extract, 9 parts of spirulina platensis, 8 parts of chlorella pyrenoidosa, 3.7 parts of haematococcus pluvialis, 5 parts of euglena and 0.3 part of dunaliella salina extract; the DHA content of the fish oil extract is not less than 125 mg/g.

5. The fish oil extract polyatomic tablet capable of reducing blood lipids and enhancing in-vivo fat metabolism according to any one of claims 1 to 4, wherein DHA content of the fish oil extract is not less than 135 mg/g;

preferably, the DHA content of the fish oil extract is not less than 150 mg/g;

more preferably, the EPA content of the fish oil extract is more than or equal to 80 mg/g;

6. The fish oil extract microalgae tablet capable of reducing blood lipid and enhancing fat metabolism in vivo as claimed in claim 5, wherein the fish oil extract has a total content of DHA + EPA of 230mg/g or more.

7. The fish oil extract-microalgae tablet capable of reducing blood lipid and enhancing fat metabolism according to any one of claims 1 to 4, wherein the water content of the fish oil extract is 1.0% or less.

8. The method for preparing fish oil extract-containing microalgae tablet capable of reducing blood lipid and enhancing fat metabolism as claimed in any one of claims 1 to 7, wherein the fish oil extract, spirulina platensis, chlorella pyrenoidosa, haematococcus pluvialis, euglena and dunaliella salina extract are weighed according to the mass parts, the raw materials are preheated and mixed uniformly, water is added for granulation, then drying is carried out, and the sorbitol is added for mixing and tabletting.

9. The method for preparing the catalyst according to claim 8, wherein the preheating temperature of the raw materials during mixing is 50-60 ℃;

preferably, the preheating temperature of the raw materials during mixing is 50 ℃, 52 ℃, 54 ℃, 56 ℃, 58 ℃ or 60 ℃;

preferably, the mixing and stirring time of the raw materials is 20-40 min;

preferably, the raw materials are mixed and stirred for 20min, 25min, 30min, 35min or 40 min;

preferably, the temperature of the added water is 38 ℃ to 42 ℃;

10. The method of claim 8, wherein the drying temperature is 55-60 ℃, and the moisture content of the dried granules is 3-5 wt%;

preferably, the moisture content of the dried granules is 3%, 3.5%, 4%, 4.5% or 5%.